Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP decreased its position in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 81.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 41,661 shares of the company’s stock after selling 184,761 shares during the quarter. Wellington Management Group LLP’s holdings in Dyne Therapeutics were worth $1,496,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new position in Dyne Therapeutics in the 2nd quarter valued at $217,000. Nisa Investment Advisors LLC increased its stake in Dyne Therapeutics by 904.1% in the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after purchasing an additional 669 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Dyne Therapeutics by 52.5% during the second quarter. Bank of New York Mellon Corp now owns 311,504 shares of the company’s stock worth $10,993,000 after buying an additional 107,233 shares during the period. Legato Capital Management LLC boosted its stake in Dyne Therapeutics by 35.3% in the 2nd quarter. Legato Capital Management LLC now owns 15,480 shares of the company’s stock worth $546,000 after buying an additional 4,035 shares during the last quarter. Finally, Lisanti Capital Growth LLC boosted its stake in Dyne Therapeutics by 22.5% in the 2nd quarter. Lisanti Capital Growth LLC now owns 106,140 shares of the company’s stock worth $3,746,000 after buying an additional 19,530 shares during the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DYN has been the topic of several recent analyst reports. StockNews.com lowered shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Robert W. Baird initiated coverage on shares of Dyne Therapeutics in a research note on Friday, December 13th. They set an “outperform” rating and a $46.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. Piper Sandler reaffirmed an “overweight” rating and issued a $53.00 target price on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Finally, JPMorgan Chase & Co. downgraded Dyne Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $43.00 to $35.00 in a research report on Thursday, October 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Dyne Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $50.42.

Dyne Therapeutics Stock Performance

Shares of NASDAQ:DYN opened at $24.56 on Thursday. The business’s 50-day simple moving average is $29.99 and its 200 day simple moving average is $35.11. The company has a market cap of $2.50 billion, a P/E ratio of -6.90 and a beta of 1.09. Dyne Therapeutics, Inc. has a one year low of $11.66 and a one year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). Analysts predict that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Dirk Kersten sold 79,411 shares of Dyne Therapeutics stock in a transaction on Friday, September 20th. The shares were sold at an average price of $36.45, for a total value of $2,894,530.95. Following the completion of the sale, the director now owns 234,127 shares in the company, valued at approximately $8,533,929.15. The trade was a 25.33 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Richard William Scalzo sold 1,455 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $40,914.60. Following the transaction, the senior vice president now owns 127,078 shares in the company, valued at $3,573,433.36. This trade represents a 1.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 167,341 shares of company stock valued at $5,862,564 in the last quarter. Company insiders own 20.77% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.